CLNNConsumer Defensive · Packaged FoodsThe 5 Wall Street analysts covering Clene, Inc. hold a median 12-month price target of $30 — +673.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 23 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Clene, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (93): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CLNN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +673.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $31 |
| 4 May 2026 | D. Boral Capital | Maintains | Buy | $23 |
| 4 May 2026 | D. Boral Capital | Maintains | Buy | — |
| 4 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $31 |
| 4 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 12 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 10 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 25 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Sept 2025 | Benchmark | Maintains | Buy | — |
| 21 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 14 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 May 2025 | Benchmark | Maintains | Buy | — |
| 8 May 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CLNN appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Clene, Inc. returned −52.4% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 2% of US stocks
Cheaper than 95% of US stocks
Cheaper than 77% of US stocks
Higher than 96% of US stocks
Higher than 91% of US stocks
Higher than 73% of US stocks
Higher than 2% of US stocks
Higher than 98% of US stocks
Higher than 97% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Clene, Inc. has a market value of $53.4M and an enterprise value of $61.0M.
Revenue in the twelve months to 30 June 2026: $197K. The latest quarter grew 233.3% year on year.
Net income over the same four quarters: −$39.5M, a −20059.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$15.9M.
Trailing P/E: −1.4×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Clene, Inc. employs 76 people — $3K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Clene, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Clene announced that it submitted a New Drug Application to the FDA earlier in October, seeking accelerated approval of CNM-Au8 for the treatment of ALS.
Why it matters — The submission is a regulatory milestone for Clene’s CNM-Au8 program in ALS.
Clene said it plans to submit a new drug application to the U.S. FDA at the start of the fourth quarter for CNM-Au8, its investigational ALS treatment. The company is targeting a decision around mid-2027.
Why it matters — This filing milestone for Clene's lead ALS candidate moves the company closer to potential regulatory review and a possible decision on CNM-Au8.
Clene Inc. announced that management will participate in the 5th Annual ROTH Healthcare Opportunities Conference and the Lytham Partners Investor Conference Fall Event, hosting 1x1 investor meetings at both conferences.
Why it matters — The conference appearances give Clene's management an opportunity to present the company to investors and participate in one-on-one meetings, which could raise its profile in the investment community.
Clene announced the closing of a registered direct offering of common stock to existing shareholders, including insiders, raising $4 million in gross proceeds. The company said the funding extends its capital runway beyond the expected FDA decision on its CNM-Au8 New Drug Application.
Why it matters — The offering strengthens Clene's cash position through the anticipated FDA decision on its ALS treatment, reducing near-term funding concerns for CLNN watchers.
Clene Inc. announced the pricing of a registered direct offering of 1,219,513 shares at $3.28 per share, led by its Chairman, CEO, founding investor Kensington Capital Holdings, and other existing shareholders, for total gross proceeds of $4 million. The company expects the proceeds to fund operations through mid-first quarter 2027.
Why it matters — A CLNN watcher would care because this capital raise extends the company's operating runway to mid-first quarter 2027, with participation from existing shareholders and insiders including the Chairman and CEO.
The 5 Wall Street analysts covering Clene, Inc. have a median 12-month price target of $30, with estimates ranging from $20 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Clene, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Clene, Inc. 20 out of 100 across roughly 4,600 US stocks as at 23 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Oct 2026, Clene, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (93 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +673.2% from the last close, and Ticker Nerd's factor model ranks Clene, Inc. 20 out of 100 as at 23 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Clene, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLNN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $50 over the next 12 months.
Clene, Inc. returned -52.4% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology therapeutics for neurodegenerative diseases.
The most recent item we track (GlobeNewsWire, 19 Oct 2026): "Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS". Clene announced that it submitted a New Drug Application to the FDA earlier in October, seeking accelerated approval of CNM-Au8 for the treatment of ALS.
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology therapeutics for neurodegenerative diseases. Clene Inc. develops oral nanotechnology-based drug candidates designed to support neuronal health and function, with programs centered on conditions such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. Its current portfolio includes investigational therapies and related platform technologies aimed at improving mitochondrial function, protecting neurons, and supporting remyelination. The company also operates activities in dietary supplements, leveraging its nanocrystal manufacturing capabilities to produce low-concentration supplement products. Headquartered in Salt Lake City, Utah, Clene Inc. plays a specialized role in the pharmaceutical market by advancing novel approaches for central nervous system disorders and related neurological conditions.
CEO Mr. Robert Etherington MBA · 76 employees · United States · https://clene.com
